We studied 128 patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (SCT). Disease at the time of treatment with Imatinib was in chronic phase (CP) in 51 patients, accelerated phase (AP) in 31 and blastic crisis (BC) in 46. Of the 51 patients in CP, 14 were in cytogenetic and two in molecular relapses. The median interval between relapse and Imatinib therapy was 5 months (0-65). A total of 50 patients had failed treatment with donor lymphocyte infusions prior to Imatinib. The overall hematological response rate was 84% (98% for patients relapsing in CP). The complete cytogenetic response (CCR) was 58% for patients in CP, 48% for AP and 22% for patients in BC. Complete molecular responses were obtained in 25 patients (26%), of whom 21 were in CP or AP. With a median follow-up of 9 months, the estimated 2-year survival for CP, AP and BC patients was 100, 86 and 12%, respectively. Out of 79 evaluable patients, 45 (57%) achieved full donor and 11 (14%) mixed chimerism after Imatinib. We conclude that Imatinib has significant activity against CML in relapse after allogeneic SCT. Durable cytogenetic and molecular remissions are obtainable in patients in CP.
Introduction
Allogeneic hematopoietic stem cell transplantation (SCT) is currently the only approach capable of curing patients with chronic myeloid leukemia (CML).
1 One of the major causes of treatment failure after allo-SCT is relapse. The relapse rate is very low for patients allografted in chronic phase (CP) with unmanipulated cells, but is much higher when donor marrow cells are T-cell depleted. Approaches to treat patients with CML in relapse after allografting include alpha-interferon, chemotherapy, second SCT and immunomodulation with donor lymphocyte infusions (DLIs). 2, 3 Although DLI can restore durable molecular remissions in a high percentage of patients with CML relapsing in CP after allografting, a significant proportion of patients fails DLI therapy due to disease progression or toxicity, such as graft-versus-host disease (GHVD), associated with the procedure. [2] [3] [4] The bcr-abl oncoprotein is a constitutively activated tyrosine kinase now considered to be the principal 'cause' of the CP of CML. 5, 6 Imatinib (STI571) inhibits the Abl tyrosine kinase and thus blocks the proliferation of CML cell lines and clonogenic CML progenitor cells. [5] [6] [7] Imatinib was first administered to patients with CML in 1998 and results from phase I/II trials suggest that complete cytogenetic remission (CCR) can be obtained in 6-14% of patients with advanced phase and 35-66% of patients in CP. [8] [9] [10] [11] [12] [13] The drug is given orally, is well tolerated, and has a manageable side effect profile.
The initial phase II trials allowed only for patients who relapsed after allo-SCT into advanced phases to be treated with Imatinib. Although subsequent trials permitted the treatment with Imatinib of a wider variety of patients, including those relapsing in molecular, cytogenetic or CP relapse, very few publications of the use of Imatinib in relapse after allo-SCT have been reported to date. [14] [15] [16] [17] [18] This retrospective study summarizes the experience of 32 centers in treating 128 such patients.
Patients and methods

Patients
Between 1999 and 2001, five phase II clinical trials for patients with CML (Novartis 0102, 0109, 0113, 0114 and 0115) allowed for patients who had relapsed following an allogeneic SCT to receive treatment with Imatinib. In general, treatment was started at a dose of 400 mg once daily for patients in CP and 600 mg once daily for patients in accelerated phase (AP) and blast crisis (BC). No additional chemotherapy apart from hydroxyurea was added. Short interruptions of therapy and dose reductions were made according to the respective protocol in case of grade III-IV toxicities.
The chronic leukemia working party of the European Group of Blood and Marrow Transplantation (EBMT) sent a questionnaire to participating centers to provide retrospective data on patients treated with Imatinib as part of the treatment of relapse of CML after allogeneic SCT. A total of 128 patients with confirmed Philadelphia chromosome and/or bcr-abl-positive CML in different phases of the disease were reported. A second questionnaire was sent to request updated follow-up on these patients. In most patients full data were recorded but for some areas of the study, the proportion of missing data varied from 5 (date of birth) to 37% (chimerism data) of the total cohort of patients (Table 1) .
Definition of CML phases
BC was defined by at least 30% blasts in peripheral blood and/or bone marrow aspirates and/or the presence of extramedullary leukemic involvement. AP CML was defined as either X10 to o30% blasts in peripheral blood or marrow, or X30% blasts plus promyelocytes in peripheral blood or marrow (provided that o30% blasts were present), or X20% basophils, or thrombocytopenia corresponding to platelet counts of o100 Â 10 9 /l, unrelated to therapy. Criteria for AP CML needed to be demonstrated within 4 weeks prior to enrollment. CP patients were characterized by having less than 10% blasts, less than 30% blasts plus promyelocytes and less than 20% basophils in peripheral blood or bone marrow. In addition, patients should have no evidence of extramedullary leukemic involvement and no secondary cytogenetic aberration, other than t (9;22) . Patients with only evidence of relapse at the cytogenetic or molecular level were pooled with the CP patients.
Hematologic responses
According to the study protocol for patients in CML, BC and AP, complete hematologic remission required adequate bone marrow cellularity with a blast count of o5%, no peripheral blasts, neutrophil count 41.5 Â 10 9 /l, platelet count of 4100 Â 10 9 /l and no evidence of extramedullary involvement. No evidence of leukemia in peripheral blood and bone marrow, without full peripheral blood recovery required all of the following: blast count of o5% in bone marrow, no peripheral blood blasts, neutrophil count 41.0 Â 10 9 /l, platelet count of 420 Â 10 9 /l and no evidence of extramedullary involvement. Return to CP hematopoiesis required all of the following: blasts in peripheral blood or bone marrow o10%, percentage of blasts plus promyelocytes in peripheral blood or bone marrow o30% and peripheral blood basophils o20%. For patients in CML CP, a complete hematologic response was defined as normalization of peripheral blood counts with a normal WBC differential and no immature granulocytes present. No evidence of leukemia and return to CP were classified as partial responses.
Cytogenetic responses
G-banding cytogenetic studies were done at the participating institutions following local protocols. All patients who died of complications or progressive disease were considered to be nonresponders from the cytogenetic point of view and were included in the analysis. All patients known to be in partial or no hematological response were considered to be 100% Philadelphia positive and were included in the cytogenetic analysis. Complete cytogenetic remission was defined as the absence of Philadelphia-positive metaphases in conventional cytogenetic analysis. Partial cytogenetic response was defined as the presence of 1-99% of Philadelphia-positive metaphases in conventional cytogenetic analysis. This was divided into major (1-35%) and minor (36-99%) cytogenetic responses, respectively.
Molecular responses
Reverse transcription polymerase chain reaction (RT-PCR) for the presence of bcr-abl transcripts was performed in blood and/ or bone marrow at the participating institutions following local protocols at variable intervals. Complete molecular response required a negative result by nested or real-time quantitative RT-PCR. All patients who died of complications or progressive disease were considered to be nonresponders from the molecular point of view and were included in the analysis. All patients known to be in partial or no hematological response and all patients known to have any degree of Philadelphia chromosome positivity were considered to be PCR positive and were included in the molecular analysis.
Chimerism studies
Chimerism studies were performed at the local institution at variable time intervals. In the majority of cases, the sample analyzed was peripheral blood (46 cases), bone marrow (32 cases) or both (eight cases). The method used was predominately PCR for variable number tandem repeat (VNTR) or single tandem repeat (STR) polymorphism. VNTR/STR was used in 50 patients, while conventional cytogenetics or FISH for XX/XY mismatches was used in 21 cases. The majority of peripheral blood and all of the bone marrow analysis were performed without lineage separation and results are expressed as nonlineage-specific chimerism. Results were classified as full donor chimerism if it showed greater than 95% donor cells. Full recipient chimerism was defined as less than 5% donor cells. Mixed chimerism included patients with 5-95% donor cells.
Statistical methods
Fisher's exact test, the w 2 test or w 2 trend test, and the MannWhitney test were employed to compare groups where appropriate. Survival probabilities were calculated by the method of Kaplan-Meier. The log-rank test was used to compare survival curves. All quoted P-values are two sided, and confidence intervals (CI) refer to 95% boundaries. a Some patients received more than one treatment.
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Results
Patient characteristics
A total of 128 patients with CML underwent an allogeneic SCT and relapsed ( (Table 1) .
Disease at the time of therapy with Imatinib was in CP in 51 patients, AP in 31 and BP in 46, of which 42 were myeloid and four lymphoid. Of the 51 patients in CP, 14 were in cytogenetic and two in molecular relapse. Median time from SCT to relapse was 9 months (range 1 month to 8 years). A total of 87 patients (68%) received some form of treatment prior to Imatinib. Of these, 50 patients had failed (or progressed) to respond to DLIs, including 21 patients in chronic phase. In all, 17 of these patients also received alpha-interferon together with DLI. Of all, 14 more patients in CP were treated with alpha-interferon alone. Several combinations of chemotherapy were used to treat 41 of the 46 patients in BP prior to Imatinib therapy. At the time of treatment with Imatinib, all CP patients remained in CP. Seven AP patients had responded to previous therapy achieving a stable CP. Eight patients relapsing in BC responded transiently to chemotherapy (7DLI), although six of them were in overt BC by the time Imatinib therapy was instituted.
Concomitant therapy
Obviously, most patients were treated with several medications at the same time Imatinib therapy was implemented. A total of 18 patients were receiving immunosuppressive agents (steroids, cyclosporin A, tacrolimus and/or mycophenolate mofetil) for treatment (16 patients) or prevention (two patients) of GVHD. Only eight patients received DLI after starting treatment with Imatinib. All were off immunosuppression and four of them had received DLI previously. No patient received any form of chemotherapy concomitantly with Imatinib.
Response to Imatinib
The overall hematological response rate (Table 2) for the entire group was 84% (104 of 123 evaluable patients). It was 98% (49/ 50) for patients relapsing in CP, 93% (27 of 29) for AP and 64% (28 of 44) for BP patients (P ¼ 0.01). The hematologic response was complete in 87 patients and partial in 17 patients (three AP and 14 BC). Six more patients in BC achieved a complete hematological remission in the context of peripheral pancytopenia.
The cytogenetic response to Imatinib was assessed in 105 patients, including patients in whom the cytogenetic data were missing, but were known to have disease at the hematological level. A total of 44 achieved a CCR and 13 patients a partial remission (major in 10 and minor in three patients), giving an overall cytogenetic response rate for evaluable patients of 54%. The overall (CCR+PR) cytogenetic response was 71% for CP patients, 67% for AP patients and 30% for BC patients. The CCR rate was 44%. For patients in CP the CCR rate was 58%, for AP patients was 48% and was 22% for patients in BC.
Information on molecular analysis was obtained on 96 patients, including patients in whom the molecular data were missing but were known to have disease at the hematological or cytogenetic level. The overall complete response rate was 26% (25 patients). It was 37, 33 and 11% for patients in CP, AP and BC respectively. Only four patients in BC achieved a molecular response and this was transient in all four cases.
GVHD and chimerism
In all, 30 patients (23%) had GVHD (three acute and 27 chronic) at the time treatment with Imatinib was initiated. Of the 27 patients with chronic GVHD, 14 had limited skin involvement only. In total, 13 patients suffered from extensive chronic GVHD affecting the lungs (three patients), the gastrointestinal system (two patients) and the skin7liver (eight patients). Only three patients had an exacerbation of a pre-existing GVHD after initiating therapy with Imatinib. No patient experienced 'de novo' GVHD.
Chimerism studies were available for 98 patients (77%) at the time of starting Imatinib (Table 3) . Five patients had full donor chimerism by VNTR analysis (two patients in molecular and three in cytogenetic relapse). A total of 34 patients had mixed chimerism and 59 patients were fully recipient at the time Imatinib was started. Of these, 11 more patients were in BP (and presumably with full recipient chimerism) but had no chimerism studies performed. Results from chimerism studies after treatment with imatinib were available for 79 patients (59%). A total of 45 patients (57%) achieved full donor chimerism with Imatinib. All five patients who started imatinib with full donor chimerism remained 100% donor at last follow-up. In addition, 17/34 patients who were mixed chimeras evolved to full donor chimerism. The proportion of patients who were fully recipient who achieved a full donor result was 36% (21 out of 59). Two additional patients (one BC, one AP) were also full donor chimeras after treatment with Imatinib, although the pre-Imatinib data were missing. At last follow-up, 14 patients who had relapsed in BC and achieved full donor chimerism had returned to full recipient chimerism.
Survival
With a median follow-up of 9 months (2-34), 42 patients had died (36 BC and six AP) and 86 remained alive (51 CP, 25 AP and 10 BC). The estimated 2-year survival for the entire cohort was 65%. All patients treated with Imatinib for relapse into CP remained alive at last follow-up (Figure 1) . A 2-year actuarial survival for AP and BC patients was 86 and 12%, respectively (Po0.0001). In univariate analysis, the only two variables that influenced survival were disease phase at relapse (Po0.01) and achievement of hematological response to imatinib (Po0.001). All other variables, including age, sex, type of donor, time from SCT to relapse, previous therapy, presence of GVHD and achievement of full donor chimerism, did not significantly influence the survival.
When patients were divided according to the use of DLI prior to Imatinib, there was no difference in response or survival between the two groups. When patients who received DLI prior to Imatinib were excluded from the analysis (ie, only patients treated with Imatinib as first line, n ¼ 74), the same survival curves were obtained and the differences between the three stages of relapse (BC, AP and BC) remained unchanged.
Discussion
DLI have become the treatment of choice for patients in relapse after allogeneic SCT. 2, 3, 19 GVHD and marrow aplasia remain the two most important complications of DLI, but when an escalating dose schedule is used these problems are greatly reduced. In a recent EBMT study, survival after relapse was related to five factors: time from diagnosis to transplant, disease phases at transplant and at relapse, time from transplant to relapse and donor type. The effects of individual adverse risk factors were cumulative so that, patients with two or more adverse features had a significantly reduced survival (35 vs 65% at 5 years). Furthermore, DLI was less effective in patients who developed GVHD after SCT.
The characteristics of the patients population correlates with what is expected from allografted patients with CML with the exception of a higher proportion of patients in BP.
1,20 Treatment with Imatinib occurred promptly after relapse (median 5 months), but a significant proportion of patients received other treatment before Imatinib. It is notable that most patients in CP had failed to respond to DLI (7alpha-interferon), highlighting the unfavorable characteristics of this series. A significant proportion of patients did not receive DLI due to the presence of significant GVHD, although we did not specifically ask for the reasons behind the use of Imatinib in addition to or instead of other therapies. Of note, most patients in BC had progressed during or soon after standard chemotherapy. In a small number of patients an attempt to combine Imatinib with an other treatment, such as DLI, was made. However, the numbers are too small to extract any conclusion.
One of the most important findings of this study is the remarkably high rate of hematological and cytogenetic responses in all phases of the disease. The overall hematological response rate for the entire group was 84% and, 96% for patients in CP or AP. Two-thirds of patients in blastic transformation also achieved a complete or partial response. Despite some cytogenetic remissions, in BC patients the responses were short lived, indicating very clearly the need for further treatment. Imatinib could provide an opportunity window for, perhaps, DLI or a second transplant. In general, responses to Imatinib were similar to what have been observed for patients without previous allogeneic SCT. 11, 13, 21, 22 Significantly, patients in CP or AP responded better. The vast majority went into complete hematological remission and over 50% achieved a CCR. This is comparable to remissions obtained in CP patients with DLI as first-line treatment. [2] [3] [4] 19, 23 The responses for patients in AP are clearly very encouraging and better than what have been reported with DLI. This is perhaps, the most important message from our study: patients in AP after SCT might benefit from Imatinib alone or in combination with DLI.
The achievement of molecular remissions should be the ultimate goal of any transplant strategy. The lack of standardized PCR techniques in this series makes the interpretation of the data more difficult. However, all patients with a negative PCR result had a nested or real-time PCR test performed. In our series, the molecular response rate was significant and one-third of CP patients remained in molecular response at last follow-up. This is in contrast with emerging data regarding molecular responses in nontransplanted patients achieving cytogenetic remission after Imatinib therapy (Lin Kaplan-Meier survival curves for patients treated with Imatinib for relapse of CML after allogeneic SCT into CP, AP and BP. Survival is calculated from the start of treatment with Imatinib. Table 3 Chimerism studies
Full donor Mixed chimera Full recipient Total
Pre- Imatinib  5  34  59  98  Post-Imatinib  45  11  23  79 Imatinib for relapse of CML after allografting E Olavarria et al is possible that Imatinib reduces the level of residual leukemia to a minimum, but it is the graft-versus-leukemia effect that is responsible for eradication of CML below the detection level of current PCR techniques.
In parallel with the cytogenetic responses, it was encouraging to see that, in evaluable patients, a similar proportion achieved full donor chimerism by VNTR analysis. This was clearly a transient event in patients relapsing into BC and therefore should not be taken as an indicator of stable remission. Furthermore, it suggests that Imatinib should be used in those patients as a remission inducer that need to be followed by a more definitive therapy. In CP patients, the presence of full donor chimerism together with low-level molecular evidence of disease could be considered as a good final outcome if the response is proven durable.
The final evidence of the value of Imatinib in the management of patients relapsing after allogeneic SCT came from the survival analysis. All patients in CP and 86% of AP patients remained alive at the end of the study time. Despite a relatively short follow-up, these results are encouraging for patients who, in many cases failed to respond to (or did not receive) DLIs. These especially promising results for patients in AP would seem superior to those achieved with other treatment modalities and would favor the inclusion of Imatinib in future treatment strategies. However, some AP patients might have been classified as AP on the basis of a low platelet count, which after SCT has a much less significant importance, and a subset analysis was not possible. Relapse into BC confers a poor prognosis and this was not significantly altered by the use of Imatinib in this study. Our observations are in accordance with the few reports published on this field 16 (Olavarria E et al. Blood 2000; 96: 471a; abstract).
It seems significant that of the prognostic factors for survival after DLI for relapse, 2 only the stage of the disease at the time of relapse had an influence in the survival of patient treated with Imatinib. Time from SCT to relapse and type of donor (sibling vs unrelated) did not influence the response to Imatinib. Of course, two other factors (time from diagnosis to SCT and disease stage at SCT) were not analyzed due to the lack of baseline data.
One last point of note was the lack of influence of Imatinib therapy on the presence or progression of GVHD in our patients. Very few patients developed an exacerbation of GVHD and Imatinib did not appear to have triggered any new episode of GVHD. Of course, there will still be doubts about the effect of Imatinib on the immune function and GVL effect, but at least it seems safe from the GVHD point of view. Imatinib could become the preferred choice in patients with active GVHD at the time of relapse. This retrospective study shows the results of treating with Imatinib a total of 128 patients relapsing in different phases of the disease. There are obviously several and important caveats that are common to all retrospective studies: some data are missing and the quality of the data depends on the accuracy of the reporting institutions. Patients usually have been randomly selected and there is limited control over entry criteria. However, the vast majority of our patients were treated in the context of several phase II trials developed by the manufacturers of Imatinib. These clinical trials had stringent entry criteria and strict treatment rules. This harmonizes to a certain extent the dose and schedule of Imatinib for almost every patient in this report. In addition, the large number of patients included and the fact that nearly two-third of the patients were treated in six large institutions could counteract some of the drawbacks.
Despite recent progress in the treatment of relapse of CML after allo-SCT, there is still a need for alternative therapies for a significant proportion of patients. Our findings suggest that Imatinib has a significant activity against CML in relapse after allogeneic SCT. It is also possible that the combination of Imatinib and DLI will prove beneficial in some cases, thus reducing the need for higher doses of DLI and reducing the risk of complications. Patients with CP or AP seem to benefit more than patients in blastic phase do. Durable cytogenetic and molecular remissions are obtainable in patients in chronic phase, although, more follow-up is needed to establish the precise role of Imatinib in the management of CML in relapse. Finally, a new strategy may emerge from these observations: the use of Imatinib immediately after SCT may prevent relapse and increase the efficacy of reduced-intensity conditioning allo-SCT in the future.
